The short version of analytical standard fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Epimedium, also known as barrenwort, bishop's hat, fairy wings, horny goat weed, or yin yang huo (Chinese: 淫羊藿; pinyin: Yínyánghùo; Wade–Giles: Yin²-yang²-huo⁴), is a genus of flowering plants in the family Berberidaceae. The majority of the species are endemic to China, with smaller numbers elsewhere in Asia and a few in the Mediterranean region. Epimedium species are deciduous or evergreen hardy perennials. The majority have four-parted "spider-like" flowers in spring. The species used as a dietary supplement is Epimedium grandiflorum. It contains icariin, which is a weak PDE5 inhibitor, in vitro. Its clinical effects are unknown. While there is little clinical evidence to date, as sildenafil, vardenafil, and tadalafil–sold under the brand names Viagra, Levitra and Cialis–are all based on (stronger) PDE5 inhibitory action, it is thought to have erectogenic properties and is found in some men's sexual health supplements.
Catatonia associated with another mental disorder Due to another medical condition Unspecified catatonia. Diagnosis requires the presence of three or more of the following twelve psychomotor symptoms in association with a mental disorder, medical condition, or unspecified:
==== Places ==== In 2012, Doillon signed her first recording deal for three albums with Barclay (Universal Music France). Her first EP I.C.U came out in June and was produced by Étienne Daho and mixed by Philippe Zdar from the band Cassius. Doillon's first album was recorded in France over a 15 day period in the Studio La Seine with French musicians François Poggio, Marcello Guliani, Alexis Anérilles and Philippe Entressangle. Her debut album Places reached number three on the French charts. It also reached number one on Canadian iTunes, number two on French iTunes and was released through Verve in the US and decca in the UK. The artwork for the cover was done by Inez and Vinoodh. Doillon was on the cover of influential magazines Magic, Telerama and Les Inrockuptibles. The first single, "I.C.U", was followed by a video directed by Antoine Carlier, reconstituting her wanderings through Paris. Then came "Questions and Answers" directed by Gaetan Chataigner while Doillon was on tour and "Devil or Angel" directed by Christophe Acker in Scotland. In October 2012, Doillon started her first tour at French rock club La Flèche d'Or and played France, Belgium, Germany, Switzerland, Canada and England. This tour also played at Paris's Le Trianon venue. On 8 February 2013, during the Victoires de la musique ceremony (French equivalent of the Grammy's) at the Zenith of Paris, she was awarded Best Female Performer of the Year, competing alongside prestigious artists such as Françoise Hardy and Celine Dion. It was the first time a newcomer English-speaking performer won in that category.
Sources: en.wikipedia.org
In 2019, biologists with the Iowa Department of Natural Resources confirmed documentation of an American black bear living year-round in woodlands near the town of Decorah in northeastern Iowa, believed to be the first instance of a resident black bear in Iowa since the 1880s. Surveys taken from 35 states in the early 1990s indicated that American black bear populations were either stable or increasing, except in Idaho and New Mexico. The population in the United States was estimated to range between 339,000 and 465,000 in 2011, though this estimate does not include data from Alaska, Idaho, South Dakota, Texas or Wyoming, whose populations were not recorded in the survey. California has the largest population of the species in any of the 48 contiguous United States. The estimated 25,000-35,000 black bears in 2017 grew to 60,000 by 2026. In 2020 there were about 1,500 bears in Great Smoky Mountains National Park, where the population density is about two per square mile. In western North Carolina, the black bear population has increased from about 3,000 in the early 2000s to over 8,000 in the 2020s. As of 1993, known black bear populations in Mexico existed in four areas, though knowledge on the distribution of populations outside those areas has not been updated since 1959. Mexico is the only country where the species is classified as "endangered".
=== Names === Etilefrine is the generic name of the drug and its INNTooltip International Nonproprietary Name and BANTooltip British Approved Name, while étiléfrine is its DCFTooltip Dénomination Commune Française and etilefrina is its DCITTooltip Denominazione Comune Italiana. In the case of the hydrochloride salt, its generic name is etilefrine hydrochloride and this is its BANMTooltip British Approved Name and JANTooltip Japanese Accepted Name. Synonyms of etilefrine include ethylnorphenylephrine, ethylphenephrine, etiladrianol, aethyladrianol, and M-I-36. Brand names of the drug include Effortil, Circupon, Apocretin, Palsamin, Kertasin, Pressoton, Effoless, and Sanlephrin.
Headquarters Großdeutschland Reconnaissance Battalion Großdeutschland Panzer Regiment Großdeutschland Grenadier Regiment Großdeutschland Fusilier Regiment Großdeutschland Engineer Battalion Großdeutschland Artillery Regiment Großdeutschland Tank Destroyer Battalion Großdeutschland Army Anti-Aircraft Battalion Großdeutschland Assault Gun Battalion Großdeutschland Signal Battalion Großdeutschland Divisional Supply Group
"What we know about the US-Israeli attack on Iran and Tehran's retaliation". CNN. 28 February 2026. Retrieved 28 February 2026. U.S. and Israeli Strikes on Iran, C-SPAN Tracking of traffic in the Strait of Hormuz
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.